Table 1.
Baseline characteristics of study subjects
|
Pitavastatin |
Atorvastatin |
P value | |
|---|---|---|---|
| (n = 13) | (n = 13) | ||
| Age (years) |
60.1 ± 7.3 |
60.5 ± 10.3 |
0.90 |
| Male, n (%) |
6 (46.2%) |
5 (38.5%) |
0.69 |
| Type 2 Diabetes Mellitus, n (%) |
8 (61.5%) |
11 (84.6%) |
0.38 |
| Hypertension, n (%) |
10 (70.7%) |
7 (53.8%) |
0.67 |
| Coronary artery disease, n (%) |
2 (15.4%) |
0 (0.0%) |
0.14 |
| Current smoker, n (%) |
2 (15.4%) |
1 (7.7%) |
0.54 |
| Waist Circumference (cm) |
87.7 ± 6.3 |
91.7 ± 13.1 |
0.33 |
| BMI (kg/m2) |
25.2 ± 3.9 |
27.1 ± 3.8 |
0.22 |
| SBP (mmHg) |
118.2 ± 12.6 |
127.5 ± 19.6 |
0.17 |
| DBP (mmHg) |
76.2 ± 8.9 |
80.8 ± 11.1 |
0.26 |
| HR (/min) |
73.5 ± 11.7 |
75.7 ± 10.9 |
0.63 |
| Creatinine (μmol/L) |
76.9 ± 19.4 |
70.7 ± 17.7 |
0.25 |
| ALT (U/L) |
21.7 ± 13.5 |
33.6 ± 21.1 |
0.10 |
| Glucose (mmo/L) |
6.98 ± 1.39 |
6.28 ± 1.04 |
0.16 |
| A1c (%) |
6.8 ± 1.1 |
6.3 ± 0.5 |
0.18 |
| Medication |
|
|
|
| Metformin, n (%) |
8 (61.5%) |
11 (84.6%) |
0.14 |
| DPP-4 inhibitors, n (%) |
2 (15.4%) |
1 (7.7%) |
0.54 |
| PPAR-γ agonists, n (%) |
0 (0%) |
1 (7.7%) |
0.31 |
| ARB, n (%) |
3 (23.1%) |
4 (30.8%) |
0.66 |
| ACEI, n (%) |
3 (23.1%) |
2 (15.4%) |
0.62 |
| CCB, n (%) |
5 (38.5%) |
3 (23.1%) |
0.40 |
| Beta-blockers, n (%) |
2 (15.4%) |
2 (15.4%) |
1.00 |
| Diuretics, n (%) |
1 (7.7%) |
4 (30.8%) |
0.14 |
| Aspirin, n (%) | 3 (23.1%) | 1 (7.7%) | 0.28 |
Values are mean ± standard deviation (SD) or number (%). ARB: angiotensin II receptor blockers; ACEI: angiotensin converting enzyme inhibitors; BMI: body mass index; CCB: calcium channel blockers; DBP: diastolic blood pressure; HR: heart beats ALT: analine amiontransferase; DPP-4 inhibitors: dipeptidyl peptidase-4 inhibitors; PPAR-γ agonists: peroxisome proliferator activator receptor-gamma agonists, SBP: systolic blood pressure.